DelveInsight has launched a new report on “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Dyslipidemia Market Report:
According to the CDC, in 2015–2016, in the US, more than about 12% (29 million) of adults age 20 and older had total cholesterol higher than 240 mg/dL (95 million had it >200mg/dL), and more than 18% had high-density lipoprotein (HDL, or good) cholesterol levels less than 40 mg/dL. It also states that 7% of US children and adolescents ages 6 to 19 have high total cholesterol.
In Europe, EURIKA study, a total of 1591 patients (20.8%) were classified as having high TG levels (≥ 2.3 mmol/l), 1691 (22.1%) had low HDL-C levels (men < 1.0 mmol/l, women < 1.3 mmol/l), and 759 (9.9%) had both high TG and low HDL-C levels.
Key benefits of the report:
Dyslipidemia market report covers a descriptive overview and comprehensive insight of the Dyslipidemia Epidemiology and Dyslipidemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Dyslipidemia market report provides insights on the current and emerging therapies.
Dyslipidemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Dyslipidemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dyslipidemia market.
Dyslipidemia is a condition caused by the abnormal fluctuation in the levels of cholesterol as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL). Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue.
The dynamics of the Dyslipidemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Dyslipidemia Market Landscape
Dyslipidemia Pipeline Therapies and Key Companies
ARO-ANG3: Arrowhead Pharmaceuticals
Vupanorsen: Pfizer And TIMI Study Group
Gemcabene: NeuroBo Pharmaceuticals
AZD8233: AstraZeneca And Parexel
LY3475766: Eli Lilly and Company
Dyslipidemia Market Drivers
Increasing global geriatric population
Increase in the prevalence of lifestyle-related and cardiovascular disorders
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Dyslipidemia Patient Share (%) Overview at a Glance
5. Dyslipidemia Market Overview at a Glance
6. Dyslipidemia Disease Background and Overview
7. Dyslipidemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Dyslipidemia
9. Dyslipidemia Current Treatment and Medical Practices
10. Unmet Needs
11. Dyslipidemia Emerging Therapies
12. Dyslipidemia Market Outlook
13. Country-Wise Dyslipidemia Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Dyslipidemia Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States